ABOUT US
PerkinElmer At a Glance
We are a global company committed to innovating for a healthier world. We create the instruments, tests, software and services used by scientists, researchers and clinicians to address the most critical challenges across science and healthcare.
190 Countries in Operation
16,000 Employees
$5 Billion in Revenue
80+ Years of Innovation
Driving Positive Outcomes Through Precision Diagnostics
With $2.9 billion in revenue for 2021, PerkinElmer Diagnostics is a major player in the in vitro diagnostics market. Operating on a global scale, we offer innovative and complete solutions, including instruments, reagents, automation, services and software, designed to serves multiple end users and needs.
Reproductive Health
At PerkinElmer, we believe all expectant mothers should have a healthy pregnancy and all babies should have a better start in life. To do so, we provide laboratories and clinics with complete screening solutions that enable them to identify a wide range of disorders from early in the pregnancy to the first few weeks of birth.
PerkinElmer is the global leader in prenatal and newborn screening. In 2021, we screened over 735 million newborns saving the lives of 70+ babies each day.
Immunodiagnostics
EUROIMMUN, a PerkinElmer company, is a leading manufacturer of medical laboratory diagnostics worldwide and stands for innovation. The company commands extensive know-how and a broad technology base allowing in-house research, development and production to optimally meet the customer needs.
Laboratories in over 140 countries rely on our test systems as well as automation and software solutions for the diagnostics of autoimmune and infectious diseases as well as allergies, and to perform genetic analyses.
Applied Genomics
PerkinElmer’s optimized, automated solutions are designed to eliminate the challenges associated with genomic and proteomic analysis by providing labs with complete, single-source solutions encompassing everything from sample to solution.
Our COVID-19 solutions helped 75 million people throughout the world. We are working closely with laboratories around the world to deliver the SARS-CoV-2 detection, screening and surveillance solutions they need, when they need them. Our nucleic acid isolation, automation, real-time PCR and NGS library preparation solutions allow labs to rapidly respond to their SARS-CoV-2 challenges with flexible, single-source workflows.
